Interaction of milrinone with extracorporeal life support.

The journal of extra-corporeal technology Pub Date : 2024-12-01 Epub Date: 2024-12-20 DOI:10.1051/ject/2024014
Aviva J Whelan, Sabiha Mim, J Porter Hunt, Autumn M McKnite, Danielle J Green, Carina E Imburgia, Jeremiah D Momper, Gideon Stitt, Kevin M Watt
{"title":"Interaction of milrinone with extracorporeal life support.","authors":"Aviva J Whelan, Sabiha Mim, J Porter Hunt, Autumn M McKnite, Danielle J Green, Carina E Imburgia, Jeremiah D Momper, Gideon Stitt, Kevin M Watt","doi":"10.1051/ject/2024014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Milrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown.</p><p><strong>Methods: </strong>Ex vivo ECMO and CRRT circuits were primed with human blood and then dosed with milrinone to study drug extraction by the circuits. Milrinone percent recovery over time was calculated to determine circuit component interaction with milrinone.</p><p><strong>Results: </strong>Milrinone did not exhibit measurable interactions with the ECMO circuit, however, CRRT cleared 99% of milrinone from the experimental circuit within the first 2 hours.</p><p><strong>Conclusion: </strong>Milrinone dosing adjustments are likely required in patients who are supported with CRRT while dosing adjustments for ECMO based on these ex-vivo results are likely unnecessary. These results will help improve the safety and efficacy of milrinone in patients requiring ECMO and CRRT. Due to the limitations of ex-vivo experiments, future studies of milrinone exposure with ECLS should include patient circuit interactions as well as the physiology of critical illness.</p>","PeriodicalId":519952,"journal":{"name":"The journal of extra-corporeal technology","volume":"56 4","pages":"167-173"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661780/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of extra-corporeal technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1051/ject/2024014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Milrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown.

Methods: Ex vivo ECMO and CRRT circuits were primed with human blood and then dosed with milrinone to study drug extraction by the circuits. Milrinone percent recovery over time was calculated to determine circuit component interaction with milrinone.

Results: Milrinone did not exhibit measurable interactions with the ECMO circuit, however, CRRT cleared 99% of milrinone from the experimental circuit within the first 2 hours.

Conclusion: Milrinone dosing adjustments are likely required in patients who are supported with CRRT while dosing adjustments for ECMO based on these ex-vivo results are likely unnecessary. These results will help improve the safety and efficacy of milrinone in patients requiring ECMO and CRRT. Due to the limitations of ex-vivo experiments, future studies of milrinone exposure with ECLS should include patient circuit interactions as well as the physiology of critical illness.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
米力农与体外生命维持系统的相互作用。
背景:米力农常用于需要体外生命支持的危重患者,如体外膜氧合(ECMO)和持续肾替代治疗(CRRT)。目前,ECMO和CRRT对米林酮处置的影响尚不清楚。方法:在体外ECMO和CRRT回路中灌注人血,然后给药米力酮,研究体外ECMO和CRRT回路对药物的提取作用。随着时间的推移,计算米林酮的回收率,以确定电路元件与米林酮的相互作用。结果:米力农与ECMO回路没有可测量的相互作用,然而,CRRT在前2小时内从实验回路中清除了99%的米力农。结论:在接受CRRT治疗的患者中,可能需要调整米力农的剂量,而根据这些离体结果调整ECMO的剂量可能是不必要的。这些结果将有助于提高米力农在需要ECMO和CRRT的患者中的安全性和有效性。由于离体实验的局限性,米力农暴露与ECLS的未来研究应包括患者电路相互作用以及危重疾病的生理学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Enhancing lung transplantation with ECMO: a comprehensive review of mechanisms, outcomes, and future considerations. Failure to oxygenate during cardiopulmonary bypass; treatment options and intervention algorithm. Interaction of milrinone with extracorporeal life support. Plasmapheresis for extracorporeal membrane oxygenation (ECMO)-induced hemolysis in infants. List of JECT reviewers 2024.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1